計劃書編號AHX-03-103
2006-04-01 - 2007-12-31
Phase II
A phase I/II study in subjects with locally advanced, recurrent, or metastatic hepatocellular carcinoma, evaluating the safety, pharmacokinetics, and anti-tumor activity of ADH300004(eniluracil) with escalating doses of 5-fluorouracil administered orally once weekly for 3 weeks out of every 4 (Adherex Protocol Number AHX-03-103)
-
試驗委託 / 贊助單位名稱
-
臨床試驗規模
多國多中心
-
更新日期
2025/08/19
試驗主持人及試驗醫院
適應症
Anti-tumor
試驗目的
The purpose of this clinical trial is to determine what effects, good and bad, this combination of anti-cancer drugs has on patients and their disease.
藥品名稱
ADH300004(eniluracil); tablet 5-fluorouracil(5-FU);tablet
主成份
eniluracil ; 5-fluorouracil
劑型
tablet
劑量
eniluracil,2.5mg / 5-fluorouracil,5mg/tablet
評估指標
主要納入條件
試驗計畫預計收納受試者人數
-
台灣人數
0 人
-
全球人數
50 人
